GlassScriptPhysician profile
Amber M Moore
NPI 1396184222
$11,346.76
in general payments reported to CMS, 2019-2025
47 companies · $2,022 in 2025
The $2,022 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,670 · 2022: $2,109 · 2023: $2,198 · 2024: $2,347 · 2025: $2,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,555 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,554.95 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,036.48 | 2021-2025 | |
| Novo Nordisk INC | $1,827.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,160.55 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $813.17 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $591.03 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $515.43 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Pfizer INC. | $507.55 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.35 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $342.66 | 2021 | |
| Lilly USA, LLC | $290.91 | 2021-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $278.78 | 2021-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.14 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $271.81 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $252.28 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $220.82 | 2023-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.